Akeso, Inc. has issued a notice convening its annual general meeting for 29 June 2026 at 2:00 p.m. at No. 28 Xiwan Road, Cuiheng New District, Zhongshan, Guangdong, China. Key agenda items include:
• Financial Statements: Shareholders will be asked to receive and adopt the audited consolidated financial statements for the year ended 31 December 2025, together with the directors’ and auditors’ reports.
• Board Composition: Re-election of three retiring directors—executive directors Dr. Li Baiyong and Dr. Wang Zhongmin Maxwell, and non-executive director Mr. Xie Ronggang. The board will also seek authorization to fix directors’ remuneration.
• Auditor: Re-appointment of Ernst & Young as external auditor, with the board authorized to determine its remuneration.
• Share Capital Mandates: – Issuance Mandate: Directors seek authority to allot, issue, or deal with additional shares up to 20% of the company’s issued share capital (excluding treasury shares) during the mandate period. – Repurchase Mandate: Authorization to repurchase up to 10% of issued shares (excluding treasury shares) on the Stock Exchange of Hong Kong or other recognized exchanges. – Extension Mandate: Conditional on the above mandates passing, the issuance limit may be extended by the number of shares repurchased, capped at an additional 10% of issued shares.
Key Timelines: • Share register closure: 24–29 June 2026 (both days inclusive). • Last day to lodge share transfers: 23 June 2026, 4:30 p.m. • Proxy form deadline: 27 June 2026, 2:00 p.m.
Board Composition as of the notice date: Dr. Xia Yu (Chairwoman & Executive Director); executive directors Dr. Li Baiyong, Dr. Wang Zhongmin Maxwell, and Dr. Zhang Peng; non-executive director Mr. Xie Ronggang; independent non-executive directors Dr. Zeng Junwen, Dr. Xu Yan, and Mr. Tan Bo.
The notice emphasizes that the board currently has no immediate plans to issue new shares and will exercise the repurchase mandate only when deemed beneficial to the company and its shareholders.
Comments